- Home
- VEL vs KURA Comparison
VEL vs KURA Comparison
Compare VEL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- KURA
- Stock Information
- Founded
- VEL 2004
- KURA 2014
- Country
- VEL United States
- KURA United States
- Employees
- VEL N/A
- KURA N/A
- Industry
- VEL Finance: Consumer Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VEL Finance
- KURA Health Care
- Exchange
- VEL Nasdaq
- KURA Nasdaq
- Market Cap
- VEL 602.1M
- KURA 713.5M
- IPO Year
- VEL 2020
- KURA N/A
- Fundamental
- Price
- VEL $18.42
- KURA $8.44
- Analyst Decision
- VEL Buy
- KURA Buy
- Analyst Count
- VEL 5
- KURA 14
- Target Price
- VEL $21.20
- KURA $24.45
- AVG Volume (30 Days)
- VEL 99.9K
- KURA 1.7M
- Earning Date
- VEL 11-06-2025
- KURA 11-06-2025
- Dividend Yield
- VEL N/A
- KURA N/A
- EPS Growth
- VEL 26.95
- KURA N/A
- EPS
- VEL 2.22
- KURA N/A
- Revenue
- VEL $195,592,000.00
- KURA $83,279,000.00
- Revenue This Year
- VEL $3.99
- KURA $60.25
- Revenue Next Year
- VEL $29.69
- KURA $155.10
- P/E Ratio
- VEL $8.33
- KURA N/A
- Revenue Growth
- VEL 44.29
- KURA N/A
- 52 Week Low
- VEL $16.12
- KURA $5.41
- 52 Week High
- VEL $20.98
- KURA $21.40
- Technical
- Relative Strength Index (RSI)
- VEL 46.90
- KURA 60.48
- Support Level
- VEL $18.10
- KURA $8.08
- Resistance Level
- VEL $18.71
- KURA $8.58
- Average True Range (ATR)
- VEL 0.40
- KURA 0.50
- MACD
- VEL -0.12
- KURA -0.04
- Stochastic Oscillator
- VEL 27.08
- KURA 63.20
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.